NCT00393965

Multiple Dose Study of MPC-6827 in Subjects With Refractory Brain Metastases

Phase 1 Open Label, Dose Escalating, Multiple Dose Study to Determine the Safety, Tolerability, Maximum Tolerated Dose, and Pharmacokinetics of MPC-6827 Administered IV Weekly X 3, Repeated Every 28 Days, in Subjects With Refractory Brain Metastases

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 18 (actual)
• Sponsor: Myrexis Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Phase 1, Multiple dose Study of MPC-6827 in Subjects with Refractory Brain Metastases.

Conditions

• Brain Neoplasms

Interventions

Type	Name	Description
DRUG	MPC-6827	2-hour IV infusion given once weekly for 3 consecutive weeks on a 28-day cycle.

Timeline

• Start date: 2005-12-01
• Primary completion: 2007-08-01
• Completion: 2008-02-01
• First posted: 2006-10-31
• Last updated: 2008-02-13

Locations

1 site across 1 country: United States